Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cardiol Therapeutics Inc (TSX:CRDL)

1.330 -0.030 (-2.21%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 28, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	45,340
Open	1.370
Bid (Size)	1.330 (69)
Ask (Size)	1.350 (12)
Prev. Close	1.360
Today's Range	1.330 - 1.380
52wk Range	1.090 - 2.170
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

December 01, 2025

(December 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company advancing anti-inflammatory and

Via PressReach

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

December 01, 2025

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac...

Via Newsfile

Performance

YTD	-2.2%	-2.2%
1 Month	N/A	N/A
3 Month	-17.4%	-17.4%
6 Month	-33.8%	-33.8%
1 Year	-28.1%	-28.1%

More News

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

August 06, 2025

Via PressReach

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

April 16, 2025

Via Newsfile

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart

February 20, 2025

Via Newsfile

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

November 18, 2024

Via Newsfile

Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN

November 07, 2024

Via AB Newswire

Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…

October 22, 2024

Via AB Newswire

Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients

June 17, 2024

Via TheNewswire.com

Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients

June 17, 2024

Via News Direct

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

June 13, 2024

Via Newsfile

Sector Spotlight: Orphan Drug Developers With Significant Upside

June 03, 2024

Via AB Newswire

Sector Spotlight: Orphan Drug Developers With Significant Upside

June 03, 2024

Via TheNewswire.com

Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)

May 28, 2024

Via AB Newswire

Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics

May 28, 2024

Via News Direct

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

February 21, 2024

Via Newsfile

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

February 15, 2024

Via Newsfile

Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

November 01, 2023

Via Newsfile

CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects ↗

October 10, 2023

Via Benzinga

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

October 10, 2023

Via Newsfile

Cardiol Therapeutics On Track To Provide New Standard Of Care For Cardiovascular Diseases ($CRDL)

October 10, 2023

Via AB Newswire

Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)

October 02, 2023

Via AB Newswire

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis

September 19, 2023

Via Newsfile

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America

September 28, 2022

Via Newsfile

Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease

July 26, 2022

Via FinancialNewsMedia

Frequently Asked Questions

Is Cardiol Therapeutics Inc publicly traded?

Yes, Cardiol Therapeutics Inc is publicly traded.

What exchange does Cardiol Therapeutics Inc trade on?

Cardiol Therapeutics Inc trades on the Toronto Stock Exchange

What is the ticker symbol for Cardiol Therapeutics Inc?

The ticker symbol for Cardiol Therapeutics Inc is CRDL on the Toronto Stock Exchange

What is the current price of Cardiol Therapeutics Inc?

The current price of Cardiol Therapeutics Inc is 1.330

When was Cardiol Therapeutics Inc last traded?

The last trade of Cardiol Therapeutics Inc was at 01/28/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.